Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).

被引：0
|
作者：
Hubbard, Joleen M.
Ahn, Daniel H.
Jones, Jeremy Clifton
Wittenberger, Kathleen
Molnar, Levente
Lorincz, Orsolya
Somogyi, Eszter
Csiszovszki, Zsolt
Youssoufian, Hagop
Toke, Eniko Rita
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Mayo Clin, Jacksonville, FL USA
[4] Treos Bio, Veszprem, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页码：TPS283 / TPS283
页数：1
相关论文
共 50 条
  • [21] A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
    Bennouna, Jaafar
    Deslandres, Marion
    Senellart, Helene
    de Labareyre, Cecile
    Ruiz-Soto, Rodrigo
    Wixon, Claire
    Botbyl, Jeff
    Suttle, A. Benjamin
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 138 - 147
  • [22] A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
    Jaafar Bennouna
    Marion Deslandres
    Helene Senellart
    Cecile de Labareyre
    Rodrigo Ruiz-Soto
    Claire Wixon
    Jeff Botbyl
    A. Benjamin Suttle
    Jean-Pierre Delord
    Investigational New Drugs, 2015, 33 : 138 - 147
  • [23] Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
    Elez, Elena
    Cubillo, Antonio
    Alfonso, Pilar Garcia
    Middleton, Mark R.
    Chau, Ian
    Alkuzweny, Baha
    Alcasid, Ann
    Zhang, Xiaosong
    Van Cutsem, Eric
    BMC CANCER, 2024, 24 (01)
  • [24] Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
    Cousin, Sophie
    Cantarel, Coralie
    Guegan, Jean-Philippe
    Gomez-Roca, Carlos
    Metges, Jean-Philippe
    Adenis, Antoine
    Pernot, Simon
    Bellera, Carine
    Kind, Michele
    Auzanneau, Celine
    Le Loarer, Francois
    Soubeyran, Isabelle
    Bessede, Alban
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2139 - 2147
  • [25] Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial
    Benidovskaya, E.
    Huyghe, N.
    Carrasco, J.
    De Cuyper, A.
    Sinapi, I.
    Verstraelen, E.
    Goffette, P.
    Ghaye, B.
    Papier, M.
    van Maanen, A.
    Castella, M-L.
    Galon, J.
    van den Eynde, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S56 - S56
  • [26] Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
    Liu, Rui
    Ji, Zhi
    Wang, Xia
    Zhu, Lila
    Xin, Jiaqi
    Ma, Lijun
    Zhang, Jiayu
    Ge, Shaohua
    Zhang, Le
    Yang, Yuchong
    Ning, Tao
    Bai, Ming
    Duan, Jingjing
    Wang, Feixue
    Sun, Yansha
    Li, Hongli
    Deng, Ting
    Ba, Yi
    Hao, Jihui
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [27] Phase II study of combination ipilimumab, nivolumab, and panitumumab in patients with KRAS, NRAS, and BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Lee, Michael
    Loehrer, Patrick
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen
    Carlson, Cheryl
    Sanoff, Hanna
    McRee, Autumn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [28] Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)
    Zhao, Wensi
    Lei, Jun
    Ke, Shaobo
    Chen, Yuan
    Xiao, Jiping
    Tang, Ze
    Wang, Li
    Ren, Yiping
    Alnaggar, Mohammed
    Qiu, Hu
    Shi, Wei
    Yin, Lei
    Chen, Yongshun
    ECLINICALMEDICINE, 2023, 66
  • [29] Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study
    Zhang, W.
    Sun, Y.
    Jiang, Z.
    Liu, T.
    Gong, C.
    Yang, L.
    Xin, Y.
    Huang, D.
    Zhou, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S728 - S728
  • [30] Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.
    Ghiringhelli, Francois
    Chibaudel, Benoist
    Taieb, Julien
    Bennouna, Jaafar
    Martin-Babau, Jerome
    Fonck, Marianne
    Borg, Christophe
    Cohen, Romain
    Thibaudin, Marion
    Limagne, Emeric
    Fumet, Jean-David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345